Compare · IDXX vs TKNO
IDXX vs TKNO
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $44.27B, about 177.6x TKNO ($249.3M).
- Over the past year, IDXX is up 8.1% and TKNO is down 21.9% - IDXX leads by 29.9 points.
- IDXX has been more active in the news (5 items in the past 4 weeks vs 4 for TKNO).
- IDXX has more recent analyst coverage (23 ratings vs 7 for TKNO).
- Company
- IDEXX Laboratories Inc.
- Alpha Teknova Inc.
- Price
- $561.97-0.07%
- $4.63+1.87%
- Market cap
- $44.27B
- $249.3M
- 1M return
- -1.85%
- +15.61%
- 1Y return
- +8.09%
- -21.86%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- 2021
- News (4w)
- 5
- 4
- Recent ratings
- 23
- 7
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest IDXX
- Executive Vice President Fennell George converted options into 639 shares and covered exercise/tax liability with 284 shares, increasing direct ownership by 4% to 10,433 units (SEC Form 4)
- SEC Form SD filed by IDEXX Laboratories Inc.
- IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
- IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
- The Biology Came First.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Samad Sam
- SEC Form 4 filed by Director Vandebroek Sophie V.
- SEC Form 4 filed by Director Peacock Karen
- SEC Form 4 filed by Director Junius Daniel M
Latest TKNO
- SEC Form 4 filed by Director Vos Alexander
- SEC Form 4 filed by Director Robertson Brett
- SEC Form 4 filed by Director Demski Martha J
- Alpha Teknova Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
- Teknova Reports First Quarter 2026 Financial Results
- Teknova to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form DEFA14A filed by Alpha Teknova Inc.
- SEC Form DEF 14A filed by Alpha Teknova Inc.